SEP 30·seekingalpha.comMed
Arbutus gains on plans to buy back 46M shares (ABUS:NASDAQ)
Arbutus Biopharma (ABUS) announced a tender offer to repurchase 46M shares at $5 each. The company's shares rose on the news.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ABUS
Arbutus Biopharma Corp
AlphAI earnings readSecond Quarter 2026 · AUG 12Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $ABUSvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 1
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
No SEC Form 4 filings for $ABUS in the last 30 days.
See all $ABUS insider activity →Top stories · $ABUSMore →
SEP 30·globenewswire.com
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Arbutus Biopharma (Nasdaq: ABUS) announced preliminary results of its $230M modified Dutch auction tender offer, purchasing 46M shares at $5.00 each, excluding fees. The offer was oversubscribed, with proration expected. Roivant Sciences, holding 19.5% of shares, maintained its stake. Final results are pending verification.
AUG 26·simplywall.st
Is Arbutus Biopharma (ABUS) Fully Valued Following Its $230 Million Tender Offer?
Arbutus Biopharma (ABUS) launched a $230M stock repurchase tender offer, following strong share price gains. The company trades at a P/E of 6.7x, lower than US equities and biotech peers, but higher than its estimated fair P/E of 1.3x. Analysts forecast declining revenue and earnings, with risks tied to trial results and licensing progress.
ABUS sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ABUS (Arbutus Biopharma Corp). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ABUS coverage spans corporate actions and market movers.
What's driving ABUS
The buyback creates immediate demand for shares, likely supporting the price in the short term.
The tender reduces outstanding shares and may support the stock price, but the $5.00 price sets a near‑term floor.
The buyback signals confidence and may provide short‑term price support.
Potential cash infusion could improve balance sheet and enable shareholder returns.
The tender offer creates immediate buy‑side pressure and may depress the share price if the purchase price is set below current levels.
AlphAI scores every news story that mentions ABUS with an AI model for sentiment and relevance, and aggregates insider trades from Arbutus Biopharma Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ABUS
Score
Arbutus gains on plans to buy back 46M shares (ABUS:NASDAQ)
Arbutus Biopharma (ABUS) announced a tender offer to repurchase 46M shares at $5 each. The company's shares rose on the news.
1 min readArbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Arbutus Biopharma (Nasdaq: ABUS) announced preliminary results of its $230M modified Dutch auction tender offer, purchasing 46M shares at $5.00 each, excluding fees. The offer was oversubscribed, with proration expected. Roivant Sciences, holding 19.5% of shares, maintained its stake. Final results are pending verification.
2 min readIs Arbutus Biopharma (ABUS) Fully Valued Following Its $230 Million Tender Offer?
Arbutus Biopharma (ABUS) launched a $230M stock repurchase tender offer, following strong share price gains. The company trades at a P/E of 6.7x, lower than US equities and biotech peers, but higher than its estimated fair P/E of 1.3x. Analysts forecast declining revenue and earnings, with risks tied to trial results and licensing progress.
2 min read
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
Arbutus Biopharma (ABUS) shares rose 6% as Moderna (MRNA) is set to make a $950M upfront payment by July 8 under a $2.25B settlement, with ABUS receiving ~$179M. The dispute involved patented lipid nanoparticle technology used in Moderna's COVID-19 vaccine. ABUS also progresses its hepatitis B drug, imdusiran, with FDA Fast Track designation. Analysts rate ABUS a 'buy' with a $5.14 avg. price target.
2 min readArbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma (Nasdaq: ABUS) launched a US$230 million modified Dutch Auction tender offer for up to 23.2% of its shares at US$5.00–US$5.75 per share. The offer, starting August 24, 2026, expires September 29, 2026, unless extended. The company obtained exemptive relief from U.S. and Canadian regulators. The purchase price will be determined based on the tendered shares and prices.
2 min read
ABUS Jumps As Arbutus Biopharma Launches $230M Tender Offer
Arbutus Biopharma (ABUS) stock rose 10.86% after launching a $230M tender offer. The company reported Q2 revenue of $1.0M, negative EBIT, and strong balance sheet metrics, including zero net debt and $271M working capital. Analysts note bullish technical trends and a target range of $6.00–$7.00 over 6–12 months.
2 min read
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet
Arbutus Biopharma (ABUS) stock rose 7.13% on optimism about its hepatitis B pipeline and a $950M settlement with Moderna, which provided $178M in cash. The company has $92.6M in cash and minimal debt, plans a $230M share buyback, and received FDA Fast Track designation for its RNAi therapy imdusiran (AB-729). Q2 2026 revenue was $1.0M with a net loss of $5.1M.
3 min readArbutus Biopharma Corporation authorizes a Buyback Plan.
Arbutus Biopharma's board authorized a share buyback plan on August 21, 2026. The company's stock has seen a 5-day change of $5.210, with a 9.22% increase over the past year.
1 min readArbutus Biopharma Corporation announces an Equity Buyback for $230 million worth of its shares.
Arbutus Biopharma (NasdaqGS:ABUS) announced a $230 million share repurchase program, buying shares at $5.00 to $5.75 each. The offer, funded by cash on hand, is valid until September 29, 2026.
1 min readWhy is Arbutus Biopharma stock surging today?
Arbutus Biopharma (ABUS) stock rose 9.8% after announcing a $230M share repurchase plan at $5.00-$5.75 per share, funded by cash from a Moderna settlement. The buyback is set to start August 24, 2026. The company also has ongoing patent disputes with Pfizer and BioNTech. The broader market showed mild gains, but did not significantly impact ABUS's surge.
2 min read